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nsulin resistance is a characteristic fea-
ture of type 2 diabetes and plays a ma-
jor role in the pathogenesis of the
disease (1,2). Although -cell failure is
the sine qua non for development of type
2 diabetes, skeletal muscle insulin resis-
tance is considered to be the initiating or
primary defect that is evident decades be-
fore -cell failure and overt hyperglyce-
mia develops (3,4). Insulin resistance is
deﬁned as a reduced response of target
tissues(comparedwithsubjectswithnor-
mal glucose tolerance [NGT] without a
family history of diabetes), such as the
skeletal muscle, liver, and adipocytes, to
insulin. Because skeletal muscle is the pre-
dominant site of insulin-mediated glucose
uptake in the postprandial state, here we
willfocusonrecentadvancesaboutthetime
of onset, as well as the mechanism, of the
skeletal muscle insulin resistance.
RESEARCH DESIGN AND
METHODS— The euglycemic insulin
clamp technique (5) is considered to be
the gold standard for measuring insulin
action in vivo. With this technique,
whole-bodyinsulinactionisquantiﬁedas
the rate of exogenous glucose infusion
(plus any residual hepatic glucose pro-
duction) required to maintain the plasma
glucose concentration at euglycemic lev-
els in response to a ﬁxed increment in the
plasma insulin concentration. Because
80–90% of the infused glucose is taken
upbyskeletalmuscleunderconditionsof
euglycemic hyperinsulinemia, insulin
sensitivity measured with the insulin
clamp technique primarily reﬂects skele-
tal muscle (6). Another advantage of this
technique is that it can be combined with
indirect calorimetry to measure different
substrate oxidation rates and with muscle
biopsy to examine the biochemical/
molecular etiology of the insulin resistance.
Measurement of insulin sensitivity by the
frequentlysampledintravenousglucosetol-
erancetestreﬂectsbothhepaticandperiph-
eral insulin resistance and correlates well
with the insulin clamp technique (7).
Because insulin clamp studies are not
feasible in large epidemiological studies,
other surrogate markers of insulin sensi-
tivity from glucose and insulin values in
the fasting state or after an oral glucose
tolerance test (OGTT) have been devel-
oped (8–10). The homeostatic model as-
sessment correlates reasonably well with
the insulin clamp (10), but it primarily
reﬂects hepatic insulin sensitivity, since
the fasting plasma glucose is determined
mainly by the rate of hepatic glucose pro-
duction (HGP) and insulin is the primary
regulator of HGP. The correlation be-
tweenhomeostaticmodelassessmentand
the insulin clamp also is less robust when
analyzed in subgroups of glucose toler-
ance (11). During an OGTT, signiﬁcant
(30–40%) amounts of glucose are
taken up by the splanchnic bed, and HGP
is less completely suppressed than during
the insulin clamp technique (12). As a re-
sult, the plasma glucose concentration
during OGTT is affected by both hepatic
and peripheral (primarily muscle) insulin
resistance. Therefore, indexes of insulin
resistance from the OGTT, e.g., the Mat-
suda index, reﬂect both hepatic and pe-
ripheral insulin resistance and correlate
well (R value 0.70) with insulin sensi-
tivitymeasuredwiththeeuglycemicinsu-
lin clamp (9).
Normal glucose homeostasis
Skeletalmuscleisthemajorsiteofglucose
uptake in the postprandial state in hu-
mans. Under euglycemic hyperinsuline-
mic conditions, 80% of glucose uptake
occursinskeletalmuscle(13).Studiesus-
ing the euglycemic hyperinsulinemic
clamp and femoral artery/vein catheter-
ization to quantitate glucose uptake have
allowedinvestigatorstoquantifylegmus-
cleglucoseuptake.Becauseadiposetissue
uses 5% of an infused glucose load and
bone is metabolically inert, the great ma-
jority of leg glucose uptake can be ac-
counted for by skeletal muscle. During
physiological hyperinsulinemia (80–100
U/ml), leg muscle glucose uptake in-
creases linearly with time, reaching a pla-
teau value of 10 mg/kg leg weight per
minute after 60 min (13,14). In contrast,
in lean type 2 diabetic subjects, the onset
of insulin action is delayed and the ability
of insulin to maximally stimulate glucose
uptake is markedly blunted. During the
last hour of the insulin clamp, insulin-
stimulated leg muscle glucose uptake is
reducedby50%intype2diabetes(14).
These studies support the notion that the
primary defect in insulin action in pa-
tients with type 2 diabetes resides in the
skeletal muscle. Similarly, using the fore-
arm catheterization technique, a number
of investigators have demonstrated re-
duced insulin-mediated glucose uptake
by the peripheral tissues, primarily mus-
cle (15). Quantitation of leg muscle glu-
cose uptake in type 2 diabetes with
positron emission tomography has pro-
vided additional evidence for the pres-
enceofseveremuscleinsulinresistancein
type2diabetes(16).Inthepostabsorptive
state,themajority(70–75%)ofglucose
uptake (2 mg/kg per min) occurs in in-
sulin-insensitive tissues (brain, erythro-
cytes, and splanchnic tissues) (17,18),
withonly25%ofglucoseuptakeoccur-
ring in insulin-sensitive tissues. In the
postabsorptive state, total body glucose
uptake is precisely matched by the rate of
endogenous glucose production, primar-
ily by the liver and to a smaller extent by
the kidney (19). Thus, hepatic glucose
productionisthemaindeterminantofthe
fasting plasma glucose concentration and
is regulated primarily by the plasma insu-
lin and, to a lesser extent, glucagon con-
centrations (20).
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After a mixed-meal or oral glucose load,
the ensuing hyperglycemia and hyperin-
sulinemia work in concert to suppress
HGP and stimulate glucose uptake by the
splanchnic (liver) and peripheral (mus-
cle)tissues(12,21).Afterglucoseistrans-
ported into the cell, it is phosphorylated
and subsequently oxidized to carbon di-
oxideandwaterorconvertedtoglycogen,
whichcanbestoredintheliverorskeletal
muscle (22). Glycogen synthesis is regu-
lated by the enzyme glycogen synthase,
and glycolysis primarily is controlled by
the enzyme complex of pyruvate dehy-
drogenase. In humans, the rate of glucose
oxidation and the nonoxidative glucose
metabolism (primarily reﬂects glycogen
synthesis) in the insulin-stimulated state
can be estimated by indirect calorimetry
or magnetic response spectroscopy
(23,24).Approximately75%ofglucoseis
metabolized nonoxidatively, and im-
paired glycogen synthesis is one of the
earliest metabolic defects seen in the
pathogenesis of type 2 diabetes (1,2).
Intracellular pathways of glucose
disposal
Under physiologic conditions, approxi-
mately two-thirds of all glucose-6-
phosphate is converted to glycogen, and
one-thirdentersglycolysis.Oftheglucose
that enters the glycolytic pathway, the
majority (80–90%) is converted to car-
bon dioxide and water, whereas the re-
maining 10–20% is converted to lactate.
Studiesusingindirectcalorimetryandeu-
glycemic clamp technique have shown
that the glucose oxidation is more sensi-
tive (lower half-maximum) but saturates
earlier (lower maximum) than glycogen
synthesis, which has low sensitivity but
high capacity. Skeletal muscle is the pre-
dominant site of glycogen synthesis.
Molecular basis of insulin action
In the early stages of development of type
2diabetes,impairedglycogensynthesisin
muscle is the primary defect responsible
for the insulin resistance. The initial step
in muscle glucose metabolism involves
activationoftheglucosetransportsystem,
leading to inﬂux of glucose into insulin
target tissues. The free glucose that has
entered the cell is then metabolized by a
series of enzymatic steps that are under
the control of insulin. In skeletal muscle
and adipose tissue, insulin promotes glu-
cose uptake into the cells by activating a
complex cascade of phosphorylation-
dephosphorylation reactions. In skeletal
muscle,insulinbindstotheinsulinrecep-
tor leading to phosphorylation of three
key tyrosine molecules on the insulin re-
ceptor. Once the insulin receptor has
been phosphorylated, insulin receptor
substrate (IRS)-1 moves to the cell mem-
brane and becomes phosphorylated on
contiguous tyrosine molecules. Tyrosine
phosphorylation of IRS-1 results in acti-
vation of the p85 regulatory subunit of
phosphatidylinositol (PI)-3 kinase and
activates the p110 catalytic subunit, lead-
ing to an increase in phosphatidylinosi-
tol-3,4,5 triphosphate. This results in
activation of downstream protein kinase
B(alsocalledAkt)andphosphorylationof
Akt substrate 160 (AS160), which facili-
tates the translocation of GLUT4 to the
sarcolemma and subsequent entry of glu-
cose into the cell (25). Intracellular glu-
cose is rapidly phosphorylated by
hexokinase II and directed to oxidative or
nonoxidative pathways. Maintaining the
integrity of the IRS-1/PI-3 kinase/Akt
pathway is essential for normal insulin-
mediated glucose uptake in skeletal mus-
cle (26).
What is the initial metabolic defect
in the pathogenesis of type 2
diabetes?
By the time that hyperglycemia is mani-
fest, multiple metabolic abnormalities are
present in individuals with type 2 diabe-
tes. Because the majority of type 2 dia-
betic subjects are obese, they also have
daylong elevation of the plasma free fatty
acid (FFA) concentration and increased
circulating levels of inﬂammatory cyto-
kines (1,2). Because elevated plasma glu-
cose, FFA, and cytokine concentrations
all can induce insulin resistance, it is ex-
tremely difﬁcult to separate the contribu-
tion of each of these metabolic defects in
the pathogenesis of type 2 diabetes. To
examine what is the earliest defect(s) in
thedevelopmentoftype2diabetes,inves-
tigators have used two approaches. First,
one can study the lean, normal glucose
tolerant, ﬁrst-degree relatives of two par-
ents with type 2 diabetes. These individ-
ualshaveaveryhighlifetimerisk(40%)
of developing type 2 diabetes (4). In cer-
tain high-risk populations, such as Mexi-
canAmericans,theprevalenceofdiabetes
intheoffspringoftwotype2diabeticpar-
entscanreach70–80%.Theadvantageof
studying this genetically predisposed
group is that they do not have other con-
foundingfactorsthatcontributetoinsulin
resistance, such as obesity and hypergly-
cemia. Thus, they represent an ideal
modeltostudytheearlymetabolicdefects
in the pathogenesis of type 2 diabetes. A
second approach uses the long-term fol-
low-up of normal glucose tolerant sub-
jects as they progress to impaired glucose
tolerance and subsequently to type 2 dia-
betes. This prospective approach has
been used in Pima Indians (27).
What is the evidence that muscle
insulin resistance is the initial
metabolic defect in type 2 diabetes?
Multipleinvestigatorsunequivocallyhave
demonstrated that lean NGT offspring of
two parents with type 2 diabetes exhibit
moderate to severe skeletal muscle insulin
resistance (28–33). The natural history of
type 2 diabetes is depicted in Fig. A1 (all
ﬁgures can be found in an online appendix
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc09-S302/DC1) (1,34).
As Europoid individuals progress from
NGT to IGT, insulin sensitivity declines
markedly but glucose tolerance deterio-
rates minimally because of a marked
increase in insulin secretion. Similar ob-
servations have been made in Pima Indi-
ans(Fig.A2)(35)andMexicanAmericans
and Caucasians residing in San Antonio
(Fig. A3) (30,32,36). These results, span-
ningawiderangeofethnicgroups,clearly
demonstrate that insulin resistance, and
not insulin deﬁciency, initiates the se-
quence of events leading to the devel-
opment of type 2 diabetes. However,
progressive -cell failure is required
and ultimately responsible for type 2
diabetes to become fully manifest
(1,34,35,37,38).
In humans, 75–80% of insulin-
stimulated muscle glucose disposal dur-
ing a euglycemic insulin clamp is
converted to glycogen, whereas the re-
maining 20–25% is oxidized to CO2 and
H2O (39). In type 2 diabetes, impaired
glycogen synthesis secondary to reduced
glycogen synthase activity is the earliest
detectable metabolic defect (39–41).
Gulli et al. (32) studied the lean NGT off-
spring of two diabetic Mexican American
parentsusingatwo-stepeuglycemicinsu-
lin clamp (20 and 40 mU/m
2 per min)
that produced steady-state elevations in
the plasma insulin concentration of 40
and 80 U/ml, respectively, which are
close to the half-maximal suppression of
HGP and stimulation of muscle glucose
uptake and glycogen synthesis. At both
plasma insulin concentrations, glucose
uptake was decreased by 33 and 43%, re-
spectively(32)(Fig.A4).Theimpairment
in glucose uptake was accounted for en-
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metabolism (Fig. A4), which represents
glycogen synthesis. No defect was noted
inthesuppressionofhepaticglucosepro-
ductionbyinsulin(Fig.A5).Theseresults
indicate that the defect in insulin action
primarily is localized to skeletal muscle
and involves the glycogen synthetic path-
way. During both the OGTT and hyper-
glycemic clamp (Fig. A6), insulin
secretion (total, early, and late responses)
was signiﬁcantly increased, excluding a
primary defect in -cell function in the
pathogenesis of type 2 diabetes in this
ethnic population.
A similar defect in insulin-stimulated
glycogen synthesis has been reported by
Groop et al. in the Botnia study (42,43).
Usingnuclearmagneticresonance(NMR)
spectroscopy, Perseghin et al. (44) di-
rectly quantiﬁed the defect in muscle gly-
cogen synthesis in NGT offspring of two
diabetic parents. This technique allows
one to monitor glycogen synthesis nonin-
vasively over real time. These investiga-
tors demonstrated that reduced glycogen
synthesis could account for almost all of
thedecreaseininsulin-stimulatedglucose
disposal in skeletal muscle. Of note, the
severity of skeletal muscle insulin resis-
tance in the offspring of two diabetic par-
entsisofsimilarmagnitudetothatseenin
type 2 diabetic individuals.
Before the incorporation of glucose
into glycogen, it ﬁrst must be transported
into the cell and phosphorylated by hex-
okinase II to glucose-6-phosphate. Using
a novel triple isotope (
12C-mannitol,
13C-
0-methyglucose, 3-
3H-glucose) tech-
nique in combination with brachial
arterial/deep vein forearm catheterization
andtheeuglycemicclamp,Pendergrasset
al. (45) quantitated muscle glucose up-
take and phosphorylation in the insulin-
resistant NGT offspring of two type 2
diabetic parents (Fig. A7). The NGT off-
spring demonstrated a severity of whole-
body and forearm muscle insulin
resistance similar to that observed in lean
and obese type 2 diabetic subjects and in
NGT obese insulin-resistant individuals.
Similarly, the NGT offspring manifested
defects in muscle glucose transport and
phosphorylation that were similar to
those in lean and obese type 2 diabetic
subjects (Fig. A7). Using
14C-NMR to
measure muscle glucose-6-phosphate
levels,Rothmanetal.(46)demonstrateda
similar defect in combined glucose trans-
port/phosphorylation in the NGT off-
spring of two type 2 diabetic parents.
Another strategy to examine what is
the earliest defect responsible for the de-
velopment of type 2 diabetes is to pro-
spectively follow individuals who are at
high risk for the development of type 2
diabetes. This has been done by Weyer et
al. (47) in Pima Indians. At-risk individ-
uals received a euglycemic insulin clamp
to measure insulin sensitivity (primarily
reﬂects muscle) and an intravenous glu-
cose tolerance test to quantitate insulin
secretion and were followed sequentially
until they developed diabetes. At-risk in-
dividualsweremarkedlyresistanttoinsu-
lin but, at the stage of NGT, their -cells
were able to secrete sufﬁcient amounts of
insulin to offset the insulin resistance
(Fig.A8).Withtime,bothprogressors(to
type 2 diabetes) and nonprogressors (re-
mained as NGT) experienced a further
modest reduction (11–14%) in insulin
sensitivity. However, nonprogressors
were able to offset the worsening insulin
resistance in muscle by augmenting insu-
lin secretion (30%), whereas progression
to type 2 diabetes was associated with a
78% decline in the acute insulin response
to an intravenous glucose challenge (Fig.
A8). Using a similar approach, Warram et
al. (4) also demonstrated that insulin re-
sistance was a strong predictor for the fu-
ture diabetes. Because the great majority
of glucose disposal after intravenous glu-
cose administration occurs in muscle,
these results provide strong evidence that
insulin resistance in muscle is the earliest
demonstrabledefectinthenaturalhistory
of type 2 diabetes, but that the develop-
ment of overt type 2 diabetes occurs only
in those individuals whose -cells are un-
able to compensate for the defect in insu-
lin action (37,38,48,49).
Insulin resistance begets insulin
resistance
The normal -cell response to insulin re-
sistance, irrespective of the etiology of the
insulin resistance, is to increase its secre-
tion of insulin (1,2,39). However, a
chronic physiologic increase in the
plasma insulin concentration has a detri-
mental effect on skeletal muscle insulin
sensitivity. Del Prato et al. (50) demon-
strated that a 72 pmol/l (11 U/ml) in-
creaseintheplasmainsulinconcentration
in healthy NGT insulin-sensitive individ-
uals for as little as 72–96 h reduced insu-
lin-stimulated glucose disposal (insulin
clamptechnique)by30–40%.Thedefect
in insulin action was accounted for en-
tirely by impaired nonoxidative glucose
disposal (Fig. A9). On the other hand,
chroniceuglycemichyperinsulinemiadid
not alter insulin-mediated suppression of
hepatic glucose production (50). Koop-
mans et al. (51,52) showed that chronic
hyperinsulinemia (threefold increase
above baseline) in conscious rats for 7
days resulted in a reduction in insulin-
mediated total-body glucose uptake, glu-
cosestorage,andglycolysisby39,62,and
26%, respectively. Hepatic glucose pro-
duction was normally suppressed after 7
days of hyperinsulinemia. Because the
majority (80–90%) of glucose disposal
during the euglycemic insulin clamp oc-
curs in muscle, these results demonstrate
that a physiologic elevation in the plasma
insulin concentration will exacerbate the
underlying muscle insulin resistance.
Iozzo et al. (53) performed a 240-min eu-
glycemicinsulinclampstudywithmuscle
biopsies in healthy volunteers. Subjects
then received a low-dose insulin infusion
for 72 h (plasma insulin concentration
143  25 pmol/l [21  2 U/ml]), fol-
lowed by a repeat insulin clamp with
muscle biopsies. After 72 h of sustained
physiologic hyperinsulinemia, insulin-
stimulated muscle glycogen synthase ac-
tivity, total body glucose uptake, and
nonoxidative glucose disposal (primarily
reﬂects glycogen synthesis in muscle)
were signiﬁcantly reduced. Taken to-
gether,theseﬁndingsindicatethathyper-
insulinemia is not only a compensatory
response to insulin resistance, but also a
self-perpetuating cause of the defect in
muscle insulin action.
Molecular etiology of the skeletal
muscle insulin resistance in
genetically predisposed individuals
Using the euglycemic insulin clamp with
skeletal muscle biopsy, a number of in-
vestigators have examined the insulin sig-
nal transduction system in human
skeletal muscle of type 2 diabetic subjects
and consistently demonstrated defects in
IRS-1 tyrosine phosphorylation and PI-3
kinase and Akt activation (26,54,55). To
examine whether similar defects are
present in genetically predisposed indi-
viduals, Pratipanawatr et al. (36) exam-
ined insulin signaling in NGT subjects
with a strong family history of type 2 di-
abetes and demonstrated that both the
basal and insulin-stimulated IRS-1 ty-
rosine phosphorylation and PI 3-kinase
activity associated with IRS-1 were signif-
icantlydecreased(Fig.A10).Insulinstim-
ulationofPI3-kinaseactivityisarequisite
for activation of glucose transport and
glycogen synthesis. Increased serine
phosphorylationofIRS-1hasbeenshown
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phorylation of both insulin resistance
and IRS-1) in type 2 diabetes (56). In
lean insulin-resistant NGT offspring of
type2diabeticparents,increasedserine
phosphorylationofIRS-1inskeletalmus-
cle has been documented in association
with impaired activation of Akt (57) (Fig.
A11).Thus,attheearlieststageinthenat-
ural history of type 2 diabetes, i.e., the
NGT insulin-resistant offspring of two
type 2 diabetic parents, the molecular eti-
ology of the muscle insulin resistance al-
ready is well established and is virtually
identical to that in their diabetic parents.
Relationship between muscle insulin
resistance and altered FFA/muscle
lipid metabolism
Gulli et al. (32) were the ﬁrst to demon-
stratethattheNGToffspringoftwotype2
diabetic parents demonstrated marked
muscle insulin resistance but normal sen-
sitivity to the suppressive effect of insulin
on hepatic glucose production. However,
a normal basal rate of HGP in the face of
fasting hyperinsulinemia could be con-
strued to indicate the presence of hepatic
insulin resistance. More impressive was
the elevated fasting plasma FFA concen-
tration in the presence of fasting hyperin-
sulinemia and the impaired suppression
of plasma FFA during the euglycemic in-
sulin clamp (Fig. A12). These ﬁndings in-
dicate the presence of marked adipocyte
resistance to the antilipolytic effect of in-
sulin. Impaired insulin-mediated sup-
pression of whole-body lipid oxidation
also was present in the NGT offspring
(Fig. A12). Petersen et al. (58) docu-
mented an increase in intramyocellular
lipidcontentintheoffspringoftwotype2
diabetic parents. This observation is of
important clinical signiﬁcance, since di-
acylglycerol, long-chain fatty acyl CoAs,
and ceramides all have been shown to
cause serine phosphorylation of insulin
resistance and IRS-1 and lead to the de-
velopmentofinsulinresistanceinskeletal
muscle(59,60).Collectively,theseresults
suggest that intramyocellular accumula-
tionoftoxiclipidmetabolitesplaysanim-
portantroleinthepathogenesisofmuscle
insulin resistance.
To further address this question,
Kashyap et al. (30) infused a lipid emul-
sion for 4 days to cause a physiologic ele-
vationintheplasmaFFAconcentrationin
NGT insulin-resistant offspring of two
type 2 diabetes parents and in NGT insu-
lin-sensitive subjects without any family
history of diabetes. Four days of physio-
logical elevation in the plasma FFA con-
centration in the offspring did not cause
any further worsening of insulin-
stimulated whole-body glucose disposal,
nonoxidative glucose disposal, glucose
oxidation, or preexisting defects in insu-
lin-stimulated insulin receptor tyrosine
phosphorylation (30). In contrast, in
healthy control subjects, chronic lipid in-
fusion was associated with a marked de-
clineininsulin-stimulatedglucoseuptake
and insulin receptor tyrosine phosphory-
lation (30). When the insulin-resistant
offspringweretreatedwithacipimoxfor7
daystoreducetheplasmaFFAconcentra-
tion and intramyocellular FACoA con-
centration, a marked improvement in
insulin sensitivity was observed (61).
Thesedatalendfurthersupporttotheob-
servation that insulin resistance in skele-
tal muscle is an early metabolic defect in
the pathogenesis of type 2 diabetes and
that muscle lipid accumulation plays a
central role in the etiology of the muscle
insulin resistance.
Mitochondria are the main organelles
where fatty acids are oxidized and inves-
tigators have focused on their structure
and function in patients with type 2 dia-
betes. Studies using the leg balance tech-
niquehavedocumentedthatfatoxidation
is reduced in both type 2 diabetic and
obese insulin-resistant nondiabetic indi-
viduals (62), suggesting that muscle
mitochondrial oxidative capacity is im-
paired. Recently, two groups indepen-
dently showed that NGT offspring of two
type 2 diabetic parents had a reduced ex-
pression of key mitochondrial genes in-
volved in the regulation of oxidative
metabolism in skeletal muscle (63,64).
The most commonly underexpressed
functional genes were those coding for
energy generation, including multiple
glycolytic, tricarboxylic acid cycle, and
oxidative phosphorylation genes. Evi-
dence in support of a role for mitochon-
drial dysfunction as a cause of muscle
insulin resistance in the NGT offspring of
two type 2 diabetic parents has been pro-
vided by Shulman and colleagues. Using
31P-NMR, these investigators demon-
stratedimpairedmitochondrialactivityin
NGT insulin-resistant offspring of type 2
diabetic parents (57,58,65). Whereas mi-
tochondria from NGT subjects without
any family history of diabetes responded
to insulin by increasing ATP production
by 90%, mitochondria from insulin-
resistant offspring increased ATP produc-
tion by only 5% (Fig. A13). The authors
postulated that muscle mitochondrial
dysfunction was the primary defect, lead-
ing to elevated intramyocellular fatty acid
metabolites (as a consequence of reduced
fat oxidation) and subsequent insulin re-
sistance (58,66). However, recent studies
by Abdul-Ghani et al. (67) have shown
thatevensmallincreasesinpalmitoylcar-
nitine (5–10 mol/l) can markedly im-
pair ATP synthesis in mitochondria
isolated from human muscle. Thus, it is
unclear which is the cart and which is the
horse: mitochondrial dysfunction leading
to increased intramyocellular lipid con-
tent and insulin resistance or increased
muscle lipid content (i.e., secondary to
elevated plasma FFA levels and/or exces-
sive lipid ingestion) leading to mitochon-
drial dysfunction and insulin resistance.
SUMMARY— The maintenance of
normalglucosehomeostasisdependsona
ﬁnely balanced dynamic interaction be-
tween tissue (muscle, liver, and fat) sen-
sitivity to insulin and insulin secretion.
Even in the presence of severe insulin re-
sistance,aperfectlynormal-celliscapa-
ble of secreting sufﬁcient amounts of
insulin to offset the defect in insulin ac-
tion. Thus, the evolution of type 2 diabe-
tes requires the presence of defects in
both insulin secretion and insulin action,
and both of these defects can have a ge-
netic as well as an acquired component.
When type 2 diabetic patients initially
present to the physician, they will have
hadtheirdiabetesformanyyears,andde-
fects in insulin action (in muscle, liver,
and adipocytes) and insulin secretion will
be well established (1,2,39). At this stage,
it is not possible to deﬁne which defect
cameﬁrstinthenaturalhistoryofthedis-
ease and which tissue is the primary de-
fect responsible for the insulin resistance.
Althoughinsulinresistancerepresentsthe
earliest detectable abnormality in the
greatmajorityoftype2diabeticpeople,in
a minority of individuals (i.e., glucoki-
nase deﬁciency), it is clear that a -cell
defect initiates the disturbance in glucose
homeostasis. Nevertheless, it is now clear
that in any given diabetic patient, what-
everdefect(insulinresistanceorimpaired
insulin secretion) initiates the distur-
banceinglucosemetabolism,itwilleven-
tually be followed by the emergence of its
counterpart (Fig. A14).
Insulinresistanceisanearlyuniversal
ﬁndinginpatientswithestablishedtype2
diabetes. In normal-weight and obese in-
dividuals with IGT and in type 2 diabetic
subjects with mild fasting hyperglycemia
(110–140 mg/dl, 6.1–7.8 mmol/l), both
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insulin levels are increased. Although the
ﬁrst-phase insulin response may be de-
creased in some, but not all, of these sub-
jects, the ﬁrst phase consistently is
increased in the NGT offspring of two
type 2 diabetic parents and the total insu-
linresponseisincreasedinNGToffspring
and in IGT subjects. In each of these
groups, tissue sensitivity to insulin, mea-
sured with the insulin clamp technique,
has been shown to be diminished. Pro-
spective studies conclusively have dem-
onstrated that hyperinsulinemia and
insulin resistance precede the develop-
ment of IGT and that IGT represents the
forerunner of type 2 diabetes. This sce-
nario has been well documented in Pima
Indians, Mexican Americans, and Paciﬁc
Islanders.Itisnoteworthythatallofthese
populations are characterized by obesity
and a younger age at onset of diabetes.
Such results provide conclusive evidence
that insulin resistance is the inherited de-
fect that initiates the diabetic condition in
the majority of type 2 diabetic patients.
StudiesinNGTﬁrst-degreerelativesofdi-
abetic individuals and in the offspring of
two diabetic parents indicate that the in-
herited defect in insulin action results
from an abnormality in the glycogen syn-
thetic pathway in muscle and more prox-
imal defects in glucose transport/
phosphorylation and insulin signal
transduction. As the insulin resistance
progressesandmuscleglucoseuptakebe-
comes further impaired, the postprandial
rise in plasma glucose concentration be-
comes excessive, but the increase in basal
hyperinsulinemiaissufﬁcienttomaintain
the fasting plasma glucose concentration
and HGP within the normal range. None-
theless, there is an excessive postprandial
rise in plasma glucose concentration, and
a longer time is required to restore nor-
moglycemia after each meal. Eventually,
however, the insulin resistance becomes
so severe that the compensatory hyperin-
sulinemia is no longer sufﬁcient to main-
tain the fasting glucose concentration at
the basal level. The development of hy-
perglycemia further stimulates -cell se-
cretion of insulin, and the resultant
hyperinsulinemia causes a downregula-
tionofinsulinreceptornumberandofthe
intracellulareventsinvolvedininsulinac-
tion, thus exacerbating the insulin resis-
tance. Initially, the hyperglycemia-
induced increase in insulin secretion
serves a compensatory function to main-
tain near-NGT. In some individuals, the
persistent stimulus to the -cell to over-
secrete insulin leads to a progressive loss
of -cell function. Chronic hyperglyce-
mia (glucose toxicity) and/or distur-
bances in lipid metabolism (lipotoxicity)
may contribute to the defect in insulin
secretion. The resultant insulinopenia
leads to the emergence/exacerbation of
postreceptor defects in insulin action.
Many of the intracellular events involved
in glucose metabolism depend on the
surge of insulin that occurs three to four
times per day in response to nutrient in-
gestion. When the insulin response be-
comesdeﬁcient,theactivityoftheglucose
transport system becomes severely im-
paired and a number of key intracellular
enzymatic steps involved in glucose me-
tabolism become depressed. Addition-
ally, when severe insulinopenia ensues,
plasma FFA levels rise, further contribut-
ing to the defects in intracellular glucose
disposal. There is also compelling evi-
dence that hyperglycemia per se can
downregulate the glucose transport sys-
tem,aswellasanumberofotherintracel-
lular events involved in insulin action
(glucose toxicity), and a similar argument
can be made concerning the intracellular
derangement in lipid metabolism. This
pathogenetic sequence can explain all of
the clinical and laboratory features ob-
served in type 2 diabetic patients. Insofar
as the cellular defect is generalized, both
hepatic and peripheral tissues (skeletal
muscle and adipocytes), and possibly the
-cells themselves, would manifest insu-
lin resistance, and the numerous meta-
bolic alterations characteristic of the
diabetic state could be related to one and
the same primary defect.
The NGT offspring of two type 2 dia-
beticparentsalsomanifestmarkedadipo-
cyte resistance to the suppressive effects
of insulin on lipolysis. One could argue,
therefore, that the adipocyte represents
the primary tissue responsible for the in-
sulin resistance. According to this sce-
nario, the elevated plasma FFA levels
produce insulin resistance in muscle and
liver and impair -cell function. Adipo-
cytes in the NGT offspring of two type 2
diabetic parents also secrete excessive
amounts of inﬂammatory and insulin
resistance producing adipocytokines
that could initiate/exacerbate the insu-
lin resistance in skeletal muscle. As re-
viewed by Iozzo in this symposium, the
adipocyte insulin resistance could be
genetic in origin or induced in utero
duringthethirdtrimesterbynutritional
deprivation or overfeeding.
There is less evidence to support a
role for the liver as the organ responsible
for the insulin resistance. However, the
NGT offspring of two type 2 diabetic par-
ents have a normal rate of HGP in the
presence of fasting hyperinsulinemia,
suggesting the presence of hepatic resis-
tance to the suppressive effect of insulin
on glucose production. Therefore, one
could argue that the resultant fasting hy-
perinsulinemia leads to the development
of insulin resistance in skeletal muscle.
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